Body mass index and relative dose intensity does not affect the response and outcome of high-risk MDS patients treated with azacytidine. Results from the Hellenic (Greek) MDS study Group

Optimal dosing of anticancer agents is often challenging in obese and overweight patients. Apart from proper dosing issues, obesity is associated with several comorbidities and often leads to dose reductions for the fear of chemotoxicity. Body mass index (BMI) has been repeatedly shown to dismally affect outcome in several solid tumors [1,2], though its impact in hematological malignancies such as acute myeloid leukemia (AML) and diffuse large B-cell lymphoma (DLBCL) is controversial [3 –7]. For more than 10 years, azacytidine (AZA) has remained the mainstay of therapy for higher-risk myelodysplastic syndromes (MDS).

Source: Leukemia Research - July 7, 2018 Category: Hematology Authors: Sotirios G. Papageorgiou, Ioannis Kotsianidis, Christos K. Kontos, Argyris Symeonidis, Athanasios Galanopoulos, Eleftheria Hatzimichael, Elias Poulakidas, Panagiotis Diamantopoulos, Theodoros P. Vassilakopoulos, Panagiotis Zikos, Helen Papadaki, Eleni Bou Tags: Letter to the Editor Source Type: research